Beyond Weight Loss: Comparative Effects of Tirzepatide Plus Low-Energy Ketogenic Versus Low-Calorie Diet on Hepatic Steatosis and Stiffness in MASLD

What Was Tested

This controlled clinical trial paper looks at Tirzepatide.

This study aimed to compare the hepatic and metabolic effects of TZP combined with either LEKT or a conventional low-calorie diet (LCD) over a 12-week period.

Why It Was Studied

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver condition globally, strongly linked to obesity, insulin resistance, and type 2 diabetes (T2D).

However, its effect on liver-specific outcomes such as steatosis and fibrosis remains incompletely characterized.

Who Took Part

The study group was 30 participants.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

As primary endpoints, the controlled attenuation parameter (CAP, an index of hepatic steatosis) and liver stiffness measurement (LSM, an index of liver fibrosis) were assessed at the baseline and after 12 weeks using FibroScan®.

How the Study Was Run

The methods mention a period of 12 weeks.

What Was Measured

However, its effect on liver-specific outcomes such as steatosis and fibrosis remains incompletely characterized.

Topics PubMed links to this paper include Caloric Restriction, Diabetes Mellitus, Type 2, Diet, Ketogenic, Fatty Liver, Liver, Tirzepatide and Weight Loss.

Author keywords: FibroScan, MASLD, hepatic steatosis, ketogenic diet, liver stiffness and nutritional ketosis.

What This Means in Plain Language

This is a controlled clinical trial of Tirzepatide in 30 participants over 12 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2025 (Nutrients), a journal based in Switzerland.

More context: the Tirzepatide compound page, all human trials.